Myotonic Dystrophy Market Anticipates Impressive Growth Trajectory Through 2032 – Asserts DelveInsight | AMO Pharma, Harmony Biosciences, Dyne Therapeutics, Avidity, Enzerna, Juvena, NeuBase

Delveinsight Business Research LLP
The Myotonic Dystrophy Market size in the 7MM was approximately USD 80 million in the 7MM in 2021. As per DelveInsight, the Myotonic Dystrophy Market is anticipated to evolve immensely in the coming years owing to the launch of new therapies, expedited R&D activities, and the rise in the number of cases of Myotonic Dystrophy.

DelveInsight’s “Myotonic Dystrophy Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Myotonic Dystrophy market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Myotonic Dystrophy drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Myotonic Dystrophy treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Myotonic Dystrophy: An Overview

There are two main types of myotonic dystrophy (DM) — DM type 1 (DM1) and DM type 2 (DM2). DM1 is also known as Steinert disease, named after Dr. Steinert, who, along with colleagues, first described the classic form in the medical literature in 1909. DM2 is also known as Ricker syndrome proximal DM or PROMM. DM1 is further classified into congenital DM1, childhood DM1, adulthood DM1, and late-onset DM1.

DM1 and DM2 are caused by an expansion of DNA tandem repeats, resulting in an RNA gain of function mutation. DM1 is caused by the expansion of cytosine-thymine-guanine (CTG) repeat in the 3’-untranslated region of the DMPK gene on chromosome 19q13.3. DM2 results from the expansion of cytosine-cytosine-thymine-guanine (CCTG) tetranucleotide located in the intron of the CNB or ZNF9 gene on chromosome 3q21.3. DM1 is estimated to affect about 1 in 8,000–20,000 people in the general population. However, the prevalence of DM1 and DM2 varies greatly among different countries and ethnic groups.

Myotonic Dystrophy Market Key Facts

The total diagnosed prevalent patient population of Myotonic Dystrophy in the 7MM countries was close to 80,000 cases in 2021.

As per the estimates, the US had the highest patient population of Myotonic Dystrophy in 2021. Among the EU5 countries, Germany had the highest diagnosed patient population of Myotonic Dystrophy, with over 9,000 cases, followed by France in 2021. 

On the other hand, Spain had the lowest diagnosed prevalent patient population of Myotonic Dystrophy, with approximately 6,000 cases in 2021.

Key players in the global Myotonic Dystrophy market include AMO Pharma Limited, Lupin Ltd., and Harmony Biosciences, LLC. The expected entry of promising agents, including tideglusib, DYNE-101, AOC 1001, pitolisant, and mexiletine, can transform the current standard of care and market of DM during the forecast period.

Myotonic Dystrophy Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Myotonic Dystrophy pipeline therapies. It also thoroughly assesses the Myotonic Dystrophy market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the market trend for each marketed Myotonic Dystrophy drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Myotonic Dystrophy Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Myotonic Dystrophy epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Myotonic Dystrophy epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Myotonic Dystrophy Epidemiology, Segmented as –

The diagnosed prevalent cases of Myotonic Dystrophy

Type-specific diagnosed cases of Myotonic Dystrophy

Type-specific diagnosed cases of DM1

Age-specific diagnosed cases of DM

Comorbidity associated with diagnosed cases of Myotonic Dystrophy

Myotonic Dystrophy Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Myotonic Dystrophy market or expected to be launched during the study period. The analysis covers the Myotonic Dystrophy market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Myotonic Dystrophy drugs based on their sale and market share.

The report also covers the Myotonic Dystrophy pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Myotonic Dystrophy companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Myotonic Dystrophy Market Will Evolve and Grow by 2032 @


Myotonic Dystrophy Therapeutics Analysis

Currently, no approved treatment offers a permanent cure for Myotonic Dystrophy, but researchers are studying ways to help people with these disorders. Present treatment is directed toward the specific symptoms that are apparent in each individual. Therapeutic options include Pharmacological management, rehabilitative therapy, medical devices, and surgical procedures, which can be varied based on the severity of symptoms.

Several major pharma and biotech companies developing therapies for Myotonic Dystrophy. Currently, AMO Pharma is leading the therapeutics market with its Myotonic Dystrophy drug candidates in the most advanced stage of clinical development.

Myotonic Dystrophy Companies Actively Working in the Therapeutics Market Include

AMO Pharma

Harmony Biosciences

Dyne Therapeutics

Avidity Biosciences


Juvena Therapeutics

NeuBase Therapeutics

And Many Others

Emerging and Marketed Myotonic Dystrophy Therapies Covered in the Report Include:

Tideglusib: AMO Pharma

Pitolisant: Harmony Biosciences

DYNE-101: Dyne Therapeutics

Mexiletine: Lupin Ltd.

And Many More

The Report Covers an In-depth Assessment of Emerging Drugs and key Companies. Download the Sample Report to Learn More @

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Myotonic Dystrophy Competitive Intelligence Analysis

4. Myotonic Dystrophy Market Overview at a Glance

5. Myotonic Dystrophy Disease Background and Overview

6. Myotonic Dystrophy Patient Journey

7. Myotonic Dystrophy Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Myotonic Dystrophy Treatment Algorithm, Current Treatment, and Medical Practices

9. Myotonic Dystrophy Unmet Needs

10. Key Endpoints of Myotonic Dystrophy Treatment

11. Myotonic Dystrophy Marketed Therapies

12. Myotonic Dystrophy Emerging Drugs and Latest Therapeutic Advances

13. Myotonic Dystrophy Seven Major Market Analysis

14. Attribute Analysis

15. Myotonic Dystrophy Market Outlook (In US, EU5, and Japan)

16. Myotonic Dystrophy Companies Active in the Market

17. Myotonic Dystrophy Access and Reimbursement Overview

18. KOL Views on the Myotonic Dystrophy Market

19. Myotonic Dystrophy Market Drivers

20. Myotonic Dystrophy Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download the Sample PDF to Learn More About the Key Offerings of the Report @



About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Cancer Cachexia Market

“Cancer Cachexia Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Cancer Cachexia market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Cancer Cachexia market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States

Daily Digest Signup

Daily business and market business news, business management tips, market research insights, and more.


Smart public opinion research for everyone.

%d bloggers like this: